Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the "Board"). Mr. Messinger will also serve as the Chair of the Company's Audit Committee.
StockNews.com started coverage on shares of ContraFect (NASDAQ:CFRX – Free Report) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock. ContraFect Stock Down 28.0 % CFRX opened at $0.05 on Friday. The company has a market cap of $535,000.00, a price-to-earnings ratio of 0.00 and a beta […]
StockNews.com began coverage on shares of ContraFect (NASDAQ:CFRX – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. ContraFect Price Performance ContraFect stock opened at $0.05 on Friday. The stock has a market capitalization of $535,000.00, a price-to-earnings ratio of 0.00 and a […]
StockNews.com started coverage on shares of ContraFect (NASDAQ:CFRX – Free Report) in a report released on Saturday. The firm issued a sell rating on the biotechnology company’s stock. ContraFect Stock Performance Shares of NASDAQ CFRX opened at $0.05 on Friday. The firm has a market cap of $535,000.00, a P/E ratio of 0.00 and a […]